MA5-24327

antibody from Invitrogen Antibodies

Targeting: ARSB

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-24327

Provider

Invitrogen Antibodies

Product name

Arylsulfatase B Monoclonal Antibody (708401)

Antibody type

Monoclonal

Antigen

Recombinant full-length protein

Description

Reconstitute in sterile PBS to a final concentration of 0.5 mg/mL.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

708401

Vial size

100 µg

Concentration

0.5 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

MiR-29 coordinates age-dependent plasticity brakes in the adult visual cortex.

Napoli D, Lupori L, Mazziotti R, Sagona G, Bagnoli S, Samad M, Sacramento EK, Kirkpartick J, Putignano E, Chen S, Terzibasi Tozzini E, Tognini P, Baldi P, Kwok JC, Cellerino A, Pizzorusso T
EMBO reports 2020 Nov 5;21(11):e50431

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis from lysates of HepG2 human hepatocellular carcinoma cell line, Huh-7 human hepatoma cell line, and human skeletal muscle tissue. PVDF membrane was probed with 1 µg/mL of mouse Anti-human Arylsulfatase B/ARSB Monoclonal Antibody (Product # MA5-24327) followed by HRP-conjugated Anti-mouse IgG Secondary Antibody. A specific band was detected for Arylsulfatase B/ARSB at approximately 47 to 54 kDa (as indicated). This experiment was conducted under reducing conditions.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of Arylsulfatase B in HepG2 human hepatocellular carcinoma cell line, Huh-7 human hepatoma cell line, and human skeletal muscle tissue. Samples were incubated in Arylsulfatase B monoclonal antibody (Product # MA5-24327) using a dilution of 1 µg/mL followed by a HRP-conjugated Anti-Mouse IgG secondary antibody. A specific band was detected for Arylsulfatase B/ARSB at approximately 47 to 54 kDa (as indicated). This experiment was conducted under reducing conditions.

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry analysis of Arylsulfatase B in immersion fixed HepG2 human hepatocellular carcinoma cell line. Samples were incubated in Arylsulfatase B monoclonal antibody (Product # MA5-24327) using a dilution of 10 µg/mL for 3 hours at room temperature followed by NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry analysis of Arylsulfatase B in immersion fixed HepG2 human hepatocellular carcinoma cell line. Samples were incubated in Arylsulfatase B monoclonal antibody (Product # MA5-24327) using a dilution of 10 µg/mL for 3 hours at room temperature followed by NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemical analysis of Arylsulfatase B/ARSB was detected in immersion fixed HepG2 human hepatocellular carcinoma cell line using mouse Anti-human Arylsulfatase B/ARSB Monoclonal Antibody (Product # MA5-24327) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the 557-conjugated Anti-mouse IgG Secondary Antibody (re and counterstained with DAPI (blue). Specific staining was localized to cytoplasm.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

6 Figure Manipulations of miR-29a levels promote changes in PNN s A Images of WFA-labeled PNNs of scrambled-treated visual cortex (left) and miR-29a mimic (right) in young mice. Scale bar 60 mum. B, C Quantification of PNN density (scr vs. mim29a, N = 3 mice per group; t -test, P = 0.20) and intensity for each animal (scr vs. mim29a, N = 3 mice per group; t -test, P = 0.014). D Cumulative frequency of PNN staining intensity in scrambled- and mimic-treated young mice scr ( N = 1,438 cells vs. mim29a N = 1,749 cells, Kolmogorov-Smirnov test, P < 0.0001). E PNN distribution in classes of intensity in mice treated with scrambled and mimic 29a. F Images of WFA-labeled PNNs of scrambled-treated visual cortex (left) and amiR-29a LNA (right) in adult mice. Scale bar 60 mum. G, H Quantification of PNN density (scr vs. amiR-29a, N = 3 mice per group; t -test, P = 0.03) and intensity for each animal (scr vs. amiR-29a, N = 3 mice per group; t -test, P = 0.047). I Cumulative frequency of PNN intensity in scrambled and amiR-29a-treated adult mice. scr N = 1,883 cells vs. amiR-29a N = 1,937 cells, Kolmogorov-Smirnov test, P < 0.0001. J PNN distribution in classes of intensity in mice treated with scrambled and amiR-29a. K Biochemical quantification of C4S in adult amiR-29a-treated mice ( N = 5) as compared to scrambled animals ( N = 4). t -test, P = 0.0008. L Example of arylsulfatase B (ArsB) Western blot. Left: The lanes corresponding to the treated (treat scr or treat amiR-29a) and untrea